Case Study – Hemato-Oncology Multiple Myeloma
Discover how our experts helped our sponsor set up a randomized, open-label, multicentre Phase 3 study to compare progression-free survival upon two different combination therapies (with a targeted MoA) in patients with relapsed or refractory multiple myeloma.
See how we were able to handle:
- aggressive study timelines
- frequent changes to the protocol
- the adding CD138+, FISH, and cell clonality added after the study started
- Japan added as a separate study later as well
- the sponsor monitored TAT closely and wanted centralized genomics testing and aggregate reporting.
Click here to download the case study
Reach out and discover how our experts can help advance your clinical trial